Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P02649
UPID:
APOE_HUMAN
Alternative names:
-
Alternative UPACC:
P02649; B2RC15; C0JYY5; Q9P2S4
Background:
Apolipoprotein E (APOE) plays a pivotal role in lipid metabolism, acting as a key protein in the transport of lipids between organs. It is essential for the formation, conversion, and clearance of plasma lipoproteins, facilitating the distribution of lipids across tissues. APOE's interaction with various cellular receptors underscores its significance in lipid homeostasis and cholesterol management.
Therapeutic significance:
APOE's involvement in diseases such as Hyperlipoproteinemia 3, Alzheimer disease 2, Sea-blue histiocyte disease, and Lipoprotein glomerulopathy highlights its therapeutic potential. Understanding APOE's role in these conditions could lead to novel strategies for managing lipid-related disorders and neurodegenerative diseases, offering hope for targeted interventions.